Pfizer, Celltrion deal

Pfizer returned to Celltrion rights to biosimilars of Rituxan rituximab and Herceptin trastuzumab. Pfizer gained the products through its September acquisition of Hospira, which partnered with Celltrion in 2009 to develop the products. Pfizer said it is returning rights to eliminate redundancies in its biosimilar portfolio. The companies did not respond to inquiries (see BioCentury, Oct. 19, 2009 & Feb. 9, 2015). ...